Sangkil Nam

USPTO Granted Patents = 18 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 4.3

ph-index = 2

Forward Citations = 28(Granted Patents)

Location History:

South Pasadena, CA (US) (2014 - 2016)
Monrovia, CA (US) (2009 - 2017)
Tijunga, CA (US) (2018)
Duarte, CA (US) (2016 - 2022)
Tujunaga, CA (US) (2023)
Tujunga, CA (US) (2016 - 2024)

Company Filing History:

University of California

patents

5 out of 7

National and Kapodistrian University of Athens

patents

where one patent can have more than one assignee

Years Active: 2009-2024

where 'Filed Patents' based on already Granted Patents

18 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11964941 - 5-Bromo-indirubins (2024-04-23),

2. 11766442 - T-cell lymphoma treatments (2023-09-26),

3. 11584760 - Dithio ETP derivatives (2023-02-21),

4. 11524937 - Indirubin derivatives, and uses thereof (2022-12-13),

5. 11306072 - 5-bromo-indirubins (2022-04-19),

6. 11213510 - Thioindirubins (2022-01-04),

7. 11117894 - Pyridopyrazine compounds and uses thereof (2021-09-14),

8. 10822353 - Dithio ETP derivatives (2020-11-03),

9. 10703718 - 5-bromo-indirubins (2020-07-07),

10. 10435367 - Indirubin derivatives, and uses thereof (2019-10-08),

11. 10246471 - ETP derivatives (2019-04-02),

12. 9856273 - ETP derivatives (2018-01-02),

13. 9828342 - Isatin derivatives, pharmaceutical compositions thereof, and methods of use thereof (2017-11-28),

14. 9527868 - ETP derivatives (2016-12-27),

15. 9512076 - Indirubin derivatives and uses thereof in treating chronic myelogenous leukemia (2016-12-06),

Title: Celebrating the Innovations of Inventor Sangkil Nam

Introduction: Sangkil Nam is a notable inventor based in Tujunga, California, recognized for his significant contributions to the field of cancer treatment. With a total of 18 patents to his name, Nam's work focuses on developing innovative therapies that address critical healthcare challenges.

Latest Patents: Among Sangkil Nam's latest patents are groundbreaking compositions aimed at treating various forms of cancer. One such patent, titled "5-Bromo-indirubins," outlines compositions and methods specifically designed to target FLT3-AML and chronic myeloid leukemia (CML). Additionally, he has developed treatment methods for T-cell lymphoma, comprising the administration of an ETP compound to subjects in need. These advancements highlight Nam's commitment to improving treatment options for patients suffering from serious illnesses.

Career Highlights: Throughout his career, Sangkil Nam has been associated with esteemed organizations that facilitate cutting-edge research and innovation. Notably, he has worked at the City of Hope, a pioneering cancer research and treatment center, as well as the University of California, where he contributed to various scientific endeavors.

Collaborations: Nam's impactful work has led him to collaborate with renowned professionals in his field, including David A. Horne and Richard Jove. These collaborations have not only enriched his research but also broadened the horizons of medical and scientific knowledge.

Conclusion: Sangkil Nam's dedication to innovation and his impressive track record of patent contributions underline his vital role in advancing cancer treatment methodologies. As he continues to develop and refine his ideas, his innovations promise to impact many lives positively, showcasing the power of invention in improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.